Benzinga's Top Upgrades

Analysts at SunTrust Robinson Humphrey upgraded

from Neutral to Buy. The price target for Exelon has been raised from $30 to $33. Exelon shares closed at $29.70 on Friday. Barrington Research upgraded

to Outperform. USA Technologies shares closed at $2.88 on Friday. Analysts at KeyBanc upgraded

to Overweight. BioMed Realty Trust shares closed at $18.91 on Friday. Citigroup upgraded

from Neutral to Buy. The price target for Mack-Cali Realty has been raised from $22 to $24. Mack-Cali Realty shares closed at $19.64 on Friday. Analysts at Deutsche Bank upgraded

from Hold to Buy. AstraZeneca shares closed at $33.30 on Friday. Analysts at Goldman Sachs upgraded

from Neutral to Buy. The price target for Xilinx has been raised from $41 to $50. Xilinx shares closed at $41.93 on Friday. Analysts at Macquarie upgraded

from Neutral to Outperform. The price target for Oppenheimer Holdings has been raised from $25 to $27. Oppenheimer Holdings shares closed at $17.98 on Friday. Barclays upgraded

from Equal-weight to Overweight. The price target for Vertex Pharmaceuticals has been raised from $120 to $150. Vertex Pharmaceuticals shares closed at $134.06 on Friday. Citigroup upgraded

from Neutral to Buy. The price target for Ingredion has been raised from $90 to $100. Ingredion shares closed at $83.29 on Friday. KeyBanc upgraded

to Overweight. Taubman Centers shares closed at $68.26 on Friday.